Application of DCE-MRI Based on 4D FreeBreathing in Predicting the Efficacy of Immune and Targeted Therapy in Lung Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Application Value of MRI Imaging in Treatment Decision-Making for Lung Cancer.
- Who it may be relevant to
- Registry conditions: Lung Cancer. Basic parameters: 18 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study aims to address the challenge of predicting the efficacy of targeted and immunotherapy in lung cancer patients. By utilizing two DCE-MRI images-one before treatment and one after one treatment cycle-along with the patients' clinical and pathological information, we aim to achieve accurate prediction of the therapeutic efficacy of targeted and immunotherapy in lung cancer patients.
Interventions
- Diagnostic test Application Value of MRI Imaging in Treatment Decision-Making for Lung Cancer
Chest MRI scans outside of the standard treatment protocol
Primary outcome measures
- Tumor treatment response evaluation [Time frame: within one week before treatment and two weeks after treatment completion]
Eligibility criteria
Inclusion criteria
- Tumor size greater than 2 cm
- Age between 18 and 75 years
Exclusion criteria
- Presence of MRI contraindications (e.g., metal implants, pacemaker implantation, etc.)
- Allergy to gadolinium contrast agents
- Lesions difficult to delineate on images due to conditions such as atelectasis or diffuse lesions
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
China · 1 center
- Yunnan Cancer Hospital — Kunming
Identifiers
NCT: NCT06742021 · KYLX2024-272